Bysanti (milsaperidone)
Vanda Pharmaceuticals (VNDA)
ApprovedFeb 20, 2026
Marketer take
A new antipsychotic from the maker of Fanapt for schizophrenia and bipolar I mania, entering a crowded, mostly generic market where payer step edits and long-acting injectables shape the psychiatry conversation.
- Sponsor company
- Vanda Pharmaceuticals (VNDA)
- Indication
- To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder
- Therapeutic area
- Psychiatry
- Event
- FDA approval
- Date
- Feb 20, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?